AMACR and prostate carcinoma: Some morphological variants of prostatic carcinoma that pose a particular diagnostic problem and for which immunohistochemistry is particularly needed to establish the diagnosis of malignancy have been reported to express less AMACR immunoreactivity compared with their more conventional counterparts.